Leerink Partners Rates SAB Biotherapeutics (SABS) buy
Analyst Thomas Smith keeps a bullish stance on SAB Biotherapeutics with a $12.00 target, a 210.88% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Leerink Partners rated SAB Biotherapeutics, Inc. ($SABS) "buy" with a $12 price target on June 15, 2026.
Since the rating, $SABS is up 0.8% after 1 week, down 7.2% after 1 month and down 35.1% to date (from the $3.90 close on Jun 15, 2026).
SABS
SAB Biotherapeutics, Inc.
Key Points
- Leerink Partners analyst Thomas Smith reiterated a buy rating and a $12.00 price target on SAB Biotherapeutics, Inc. on June 15, 2026.
- Leerink Partners's $12 price target implies 210.88% upside from SAB Biotherapeutics, Inc.'s ($SABS) current $3.86 share price.
- Barclays also covers the stock, having initiated an overweight rating and a $13.00 price target on June 24, 2026.
- The broader analyst community tracks the clinical-stage biotech firm with a consensus mean target price of $11.64 across 11 opinions.
Get $SABS trade alerts by text
We text you when insiders, Congress or big funds trade $SABS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated SAB Biotherapeutics, Inc. alert may contain errors. Disclosures
Leerink Partners Keeps Buy Rating on SAB Biotherapeutics
On June 15, 2026, Leerink Partners analyst Thomas Smith reaffirmed his support for SAB Biotherapeutics, Inc., keeping a buy rating and a $12.00 price target on the shares. The update fits into a busy stretch of similar outlooks from the firm, which recently backed other healthcare names like MoonLake Immunotherapeutics, ABIVAX, and Rapport Therapeutics through the summer months. For SAB Biotherapeutics, this call underscores steady confidence from the investment bank as the clinical-stage firm pursues its drug pipeline.
Stock Price Trades Near Moving Averages
Shares of SAB Biotherapeutics, trading on the NasdaqCM under the ticker SABS, change hands around $3.86. The equity moves within a 52-week band spanning from a low of $1.85 up to a high of $5.15. The current price sits close to its 200-day moving average of $3.80 and near its 50-day line at $3.65. With a market value around $308.4 million, the stock continues to attract attention from healthcare investors watching its clinical progress.
$SABS price target
SAB Biotherapeutics, Inc. daily closes and this analyst's $12 target. Not advice.
Wall Street Coverage and Barclays Addition
Other financial institutions follow the biotechnology firm closely alongside Leerink Partners. On June 24, 2026, Barclays stepped in with fresh coverage, issuing an overweight rating and a $13.00 price target. Across 11 professional opinions gathered by market watchers, the consensus target price rests at $11.64. Individual forecasts span from a conservative low of $6.00 up to an upper target of $16.00, giving market participants plenty of diverse viewpoints to weigh.
Inside the Clinical Pipeline
Headquartered in Miami Beach, Florida, SAB Biotherapeutics focuses on creating human polyclonal immunotherapeutic antibodies designed to tackle immune system conditions and infectious illnesses. The organization centers its efforts around its lead candidate, SAB-142, which serves as a redosable immunotherapy moving through Phase 2b clinical trials for autoimmune type 1 diabetes. Founded back in 2014, the firm employs a team of 86 people dedicated to advancing these antibody treatments.
What to Watch Next for SABS
Investors tracking the healthcare firm will keep an eye out for its upcoming financial results scheduled for release on November 12, 2026. Beyond earnings reports, market participants continue to monitor clinical updates regarding the progress of its lead diabetes treatment. These pipeline milestones will help shape how the broader analyst community evaluates the firm's path ahead.
Related Filing Alerts
Source: Leerink Partners's rating change on $SABS (Jun 15, 2026). Written by software, not financial advice. How we make alerts